Skip to main content

St. David's Medical Center

Texas Cardiac Arrhythmia Institute First US Site for New PFA Trial

Austin – September 07, 2026 -- The Texas Cardiac Arrhythmia Institute (TCAI) at St. David's Medical Center has become the first facility in the United States to enroll in a clinical trial evaluating a next-generation mapping and pulsed field ablation (PFA) system for patients with paroxysmal and persistent atrial fibrillation.

TCAI performs first procedure under global study leadership

Andrea Natale, M.D., executive medical director of TCAI and global principal investigator for the trial, conducted the first procedure using the new catheter system. The trial is designed to assess the safety and efficacy of the technology across both forms of atrial fibrillation, the most common cardiac arrhythmia, which affects millions of patients worldwide.

TCAI Becomes First US Site to Trial New Pulsed Field Ablation System

Austin, Texas – September 7, 2026 -- The Texas Cardiac Arrhythmia Institute (TCAI) at St. David's Medical Center has become the first center in the United States to enroll a patient in a clinical trial evaluating a next-generation pulsed field ablation mapping and ablation system for paroxysmal and persistent atrial fibrillation.

TCAI performs first US procedure under global trial protocol

Andrea Natale, M.D., executive medical director of TCAI and global principal investigator for the trial, performed the inaugural procedure. The study is designed to assess the safety and efficacy of the catheter-based system in patients with paroxysmal atrial fibrillation, defined as symptomatic episodes lasting seven days or less, and persistent atrial fibrillation, sustained arrhythmia lasting longer than one week.